Shares of Compass Pathways (CMPS) rallied Monday, briefly bypassing a profit-taking zone, on growing enthusiasm for the company’s psilocybin-based approach to treatment-resistant depression. Psilocybin is the chemical ingredient found in magic mushrooms. But when paired with therapy, the company says the psychedelic experience could help rewire the brain in a way that tackles depression. Last week, Compass said the Food…
Copyright ©2026 Investor’s Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8